FFAR3 Antibody

What is FFAR3 and why is it an important research target?

FFAR3 is a G protein-coupled receptor activated by short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. It plays crucial roles in whole-body energy homeostasis and intestinal immunity. In omnivorous mammals, these SCFAs are produced primarily by the gut microbiome through dietary fiber metabolism . FFAR3 is probably coupled to the pertussis toxin-sensitive, G(i/o)-alpha family of G proteins, and its activation triggers several downstream signaling events, including inositol 1,4,5-trisphosphate formation, intracellular calcium mobilization, MAPK3/ERK1 and MAPK1/ERK2 kinase phosphorylation, and inhibition of intracellular cAMP accumulation . These pathways make FFAR3 a significant target for research in metabolic disorders, immunology, and neuroscience.

What is the molecular weight of FFAR3 and how does this affect antibody selection?

The calculated molecular weight of FFAR3 is approximately 39 kDa, but the observed molecular weight in experimental conditions typically ranges between 40-48 kDa . This discrepancy is important to consider when validating antibody specificity in Western blot applications. When selecting antibodies, researchers should verify that the product can detect FFAR3 at its expected molecular weight range. For instance, in Western blot analyses using the R&D Systems antibody on A549 and HeLa cell lines, FFAR3 was detected at approximately 39 kDa . This variation in detected molecular weight can be due to post-translational modifications or tissue-specific processing of the protein.

How should I choose between monoclonal and polyclonal FFAR3 antibodies?

The choice between monoclonal and polyclonal FFAR3 antibodies depends on your specific research application. Monoclonal antibodies like Proteintech's 66811-1-Ig (Mouse IgG1) offer high specificity for a single epitope, making them excellent for applications requiring consistent results across multiple experiments . They are particularly valuable in comparative studies where standardization is crucial.

For critical research applications, consider validating your findings with both antibody types to leverage their complementary strengths.

What species reactivity considerations are important when selecting FFAR3 antibodies?

Different FFAR3 antibodies demonstrate varying species reactivity profiles that must be carefully matched to your experimental model:

When working with mouse models, the Abbexa antibody would be the preferred choice as it has been specifically tested for mouse reactivity . For rat studies, NovoPro's antibody has demonstrated specificity in rat skeletal muscle . If your research involves human samples, either Proteintech's or R&D Systems' antibodies would be appropriate options . Always verify species cross-reactivity through literature or preliminary testing, especially when using the antibody in species listed under "cited reactivity" but not explicitly tested by the manufacturer.

What are the optimal dilutions for different FFAR3 antibody applications?

Optimal antibody dilutions vary based on the specific antibody, application, and experimental system. Below is a comparative table of recommended dilutions for various applications based on manufacturer guidelines:

For Western blot applications using Proteintech's antibody, positive detection has been reported in HepG2 cells, human adipose tissue, and HT-29 cells . For IHC applications, successful staining has been achieved in human liver cancer tissue using TE buffer pH 9.0 for antigen retrieval, with citrate buffer pH 6.0 as an alternative option . As a methodological best practice, always titrate antibodies in your specific system to determine the optimal working concentration for signal-to-noise optimization.

How can I optimize Western blot protocols for FFAR3 detection?

For optimal FFAR3 detection in Western blots, consider these methodological recommendations based on successful published protocols:

• Sample preparation: Use 25 μg of protein per lane, as validated in rat skeletal muscle extracts with the NovoPro antibody .

• Blocking conditions: 3% nonfat dry milk in TBST has been successfully used with the NovoPro FFAR3 antibody .

• Primary antibody incubation: For Proteintech's antibody, use 1:500-1:3000 dilution ; for R&D Systems' antibody, use 1 μg/mL ; for NovoPro's antibody, use 1:3000 dilution .

• Secondary antibody selection: HRP-conjugated anti-Rabbit IgG (for rabbit host antibodies) or anti-Mouse IgG (for mouse host antibodies) at 1:10000 dilution has been validated .

• Detection system: ECL Enhanced Kit has been successfully employed with exposure times around 60 seconds .

• Expected band size: Look for bands between 39-48 kDa, as FFAR3's observed molecular weight (40-48 kDa) may differ from its calculated weight (39 kDa) .

When working with R&D Systems' FFAR3 antibody, reducing conditions and Western Blot Buffer Group 1 have been successfully employed for detection in A549 and HeLa cell lines .

What are the key considerations for immunohistochemistry and immunofluorescence with FFAR3 antibodies?

For successful FFAR3 detection in tissue sections and cellular immunostaining:

• Antigen retrieval: For IHC applications with Proteintech's antibody, TE buffer pH 9.0 is recommended, with citrate buffer pH 6.0 as an alternative method . This step is critical for unmasking epitopes that may be obscured during fixation.

• Antibody dilutions: For Proteintech's antibody, use 1:200-1:800 for IHC and 1:50-1:500 for IF/ICC . For Abbexa's antibody, 5-20 μg/ml is recommended for both applications .

• Positive controls: A549 cells have been validated as positive controls for IF/ICC with Proteintech's antibody . For tissue sections, human liver cancer tissue has shown positive FFAR3 staining .

• Validation approaches: When studying FFAR3-expressing neurons, counter-labeling with different FFAR3 antibodies has been used to confirm specificity, as described in neuronal tracking studies . This approach can help validate the specificity of your staining pattern.

• Negative controls: Consider using knockout models as negative controls when available. In published research, DRG sections from FFAR3 knockout mice showed absence of immunofluorescence, confirming antibody specificity .

How can I track FFAR3-expressing neurons in research models?

For selectively tracking FFAR3-expressing neurons, researchers have employed several sophisticated approaches:

• Reporter mouse models: A successful approach involved using an Ffar3 reporter mouse model where FFAR3-expressing neurons were tagged with mRFP (monomeric red fluorescent protein) . This allows for live cell identification without antibody staining.

• Validation through counter-labeling: To confirm the fidelity of the reporter system, researchers counter-labeled mRFP-positive cells with rabbit polyclonal FFAR3 antibody to examine labeling concurrence . This dual labeling approach provides higher confidence in cell identification.

• Negative controls: Crossing reporter mice with knockout strains (Ffar3−/mRFP) creates valuable controls where neurons lack FFAR3 immunoreactivity despite fluorescent reporter expression . This helps confirm antibody specificity.

• Functional validation: Electrophysiological experiments can confirm that identified FFAR3-expressing neurons respond appropriately to FFAR3 agonists like C3 (propionate) . This functional validation is critical for neurophysiology studies.

• Experimental design considerations: When comparing wild-type and reporter models, researchers observed a 2.5-fold decrease in coefficient of variation (40% vs. 100%) in response to C3 application when using the reporter model . This highlights the importance of proper cell identification for reducing experimental variability.

What approaches can help distinguish between FFAR3 and related receptors?

Distinguishing FFAR3 from related receptors like FFAR2/GPR43 requires careful experimental design:

• Antibody selection: Choose antibodies raised against unique epitopes of FFAR3. For example, NovoPro's antibody targets amino acids 257-346 of human FFAR3 , while other antibodies may target different regions.

• Immunogen analysis: Review the immunogen information provided by manufacturers. Proteintech's antibody uses FFAR3 fusion protein Ag28025 , while Abbexa's targets recombinant FFAR3 (Ser276-Ser319) .

• Knockout validation: Utilize knockout models where available. Research has demonstrated the value of FFAR3 knockout mice (Ffar3−/mRFP) for confirming antibody specificity and receptor function .

• Pharmacological approaches: Leverage differential responses to specific agonists. While both FFAR2 and FFAR3 respond to SCFAs, they show different potency profiles that can be exploited in functional studies.

• Co-expression analysis: In certain tissues, FFAR2 and FFAR3 show distinct expression patterns that can help differentiate them. Compare your findings with established expression profiles in literature.

How can I address non-specific binding and background issues with FFAR3 antibodies?

To minimize non-specific binding and improve signal-to-noise ratio:

• Optimization of blocking conditions: 3% nonfat dry milk in TBST has been successfully used with the NovoPro FFAR3 antibody in Western blot . For other applications, consider testing BSA-based blocking buffers at various concentrations.

• Antibody dilution optimization: Always perform a dilution series to determine optimal working concentration. For Western blot, dilutions ranging from 1:500 to 1:3000 for Proteintech's antibody or 0.01-2 μg/ml for Abbexa's antibody may be appropriate starting points .

• Incubation conditions: Temperature and duration can significantly impact specificity. Overnight incubation at 4°C often provides better results than shorter incubations at room temperature.

• Washing protocol modifications: Increasing the number or duration of wash steps can help reduce background. Consider using TBS-T with 0.1-0.3% Tween-20 depending on your specific application.

• Secondary antibody selection: Choose secondary antibodies with minimal cross-reactivity to your experimental system. Pre-adsorbed secondary antibodies are recommended for multi-color immunostaining applications.

• Negative controls: Include knockout samples or secondary-only controls to assess background levels. The lack of immunofluorescence in DRG sections from FFAR3 knockout mice provides an excellent negative control example .

What storage and handling practices ensure optimal FFAR3 antibody performance?

To maintain antibody integrity and performance over time:

• Storage conditions: Most FFAR3 antibodies should be stored at -20°C for long-term preservation. Proteintech's antibody is reported stable for one year after shipment when stored at -20°C . Similarly, NovoPro recommends storage at -20°C while avoiding freeze/thaw cycles .

• Buffer composition: FFAR3 antibodies are typically supplied in PBS with preservatives. Proteintech's antibody is in PBS with 0.02% sodium azide and 50% glycerol, pH 7.3 . NovoPro's antibody uses a similar formulation .

• Aliquoting recommendations: While Proteintech notes that aliquoting is unnecessary for -20°C storage for their product , as a general best practice, dividing antibodies into single-use aliquots can prevent protein degradation from repeated freeze-thaw cycles.

• Handling during experiments: Keep antibodies on ice when in use. Allow them to equilibrate to room temperature before opening to prevent condensation that could introduce contamination.

• Shelf life considerations: R&D Systems reports their FFAR3 antibody is stable for 12 months from date of receipt at -20 to -70°C as supplied, 1 month at 2 to 8°C after reconstitution, or 6 months at -20 to -70°C after reconstitution .